Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

November 29, 2015

A paper entitled ???Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9??? was published in J. Med. Chem., 2009, 52:551-558. A paper entitled ???Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of Toll-like receptors 7 and 9??? was published in J. Med. Chem., 2009, 52:5108-5114. A presentation entitled ???IMO-3100, an antagonist of Toll-like receptors 7 and 9, modulates gene expression and regulatory networks induced by ligands??? was made at the 2009 Annual Meeting of The American Association of Immunologists in May 2009. A presentation entitled ???Antagonists of Toll-like receptors 7 and 9 and potential application for treatment of rheumatoid arthritis??? was made at the Fall 2009 National Meeting of the American Chemical Society in August 2009. A presentation entitled ???Studies of combination of IMO-3100, an antagonist of TLR7 and TLR9, and Etanercept, a TNF-alpha inhibitor, in a mouse model of collagen-induced arthritis (CIA)??? was made at the 2009 Annual Scientific Meeting of the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) in October 2009. A presentation entitled ???Modulation of TLR7 and TLR8 activation in human macrophages??? was made at the 2009 Annual Scientific Meeting of the ACR and ARHP in October 2009. A presentation entitled ???Control of atherogenic lipids by a novel antagonist of TLR7 and 9 in mouse models of hyperlipidemic disease??? was made at the Keystone Symposia Conference on Advances in Molecular Mechanisms of Atherosclerosis in February 2010. A presentation entitled ???IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates??? was made at the Keystone Symposia Conference on Tolerance and Autoimmunity in February 2010.

TLR7, 8, and 9 Agonists as Vaccine Adjuvants

A paper entitled ???Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9??? was published in Clin. Cancer Res., 2009, 15:1575-1584. A paper entitled ???Co-administration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates??? was published in Mol. Ther., 2009, 17:1804-1813. A presentation entitled ???Strategies and challenges for discovery and development of novel vaccine adjuvants??? was made at Modern Vaccine Adjuvants and Delivery Systems in October 2009. A presentation entitled ???In vitro and in vivo characterization of novel TLR9 agonists for use as vaccine adjuvants??? was made at the Cold Spring Harbor Symposium on Harnessing Immunity to Prevent and Treat Disease in November 2009. A presentation entitled ???In vitro and in vivo characterization of novel TLR9 agonists for use as vaccine adjuvants??? was made at Vaccines Europe Conference in November 2009.

TLR7, 8, and 7/8 Agonists

A paper entitled ???Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8??? was published in Biochem. Biophys. Res. Commun., 2009, 386:443-448. A paper entitled ???Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8??? was published in Bioorg. Med. Chem. Lett., 2009, 19:2044-2047. A paper entitled ???Toll-like Receptor 7 Selective Synthetic Oligoribonucleotide Agonists: Synthesis and Structure-Activity Relationship Studies??? was published in J. Med. Chem., 2009, 52, 6871-6879. A presentation entitled ???Antitumor activity of a novel dual agonist of TLR7 and TLR8 in a preclinical model of 3LL-C75 lung carcinoma in wild type, TLR7-/-, TLR9-/-, and MyD88-/- mice??? was made at the 2009 Annual Meeting of the AACR in April 2009. A presentation entitled ???Antitumor activity of a dual agonist of TLR7 and TLR8 in combination with bevacizumab in preclinical models of human non-small cell lung and colon cancers??? was made at the 2009 Annual Meeting of the AACR in April 2009.

Antisense ?? Related

A presentation entitled ???Modulation of Toll-like receptors 7 and 9 expression with antisense for potential applications in autoimmune and inflammatory diseases??? was made at the 2009 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) in June 2009. A presentation entitled ???Studies of Toll-like receptors 7 and 9 antisense in a preclinical model of colitis??? was made at the 2009 Annual Meeting of FOCIS in June 2009. A presentation entitled ???Modulation of Toll-like receptor 3 expression with antisense??? was made at the 2009 Annual Meeting of FOCIS in June 2009.

Intellectual Property

The Company??s intellectual property portfolio contains over 500 patents and patent applications worldwide.

Immune Modulatory Oligonucleotide (IMO?) Technology

In 2009, the Company??s U.S. and foreign patents and patent applications covering the Company??s TLR-targeted technologies increased by over 30 and now total 271. The following U.S. patents were issued to the Company in 2009:

US 7,632,822, entitled ???Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Utilizing Modified Immunostimulatory Dinucleotides??? US 7,595,305, entitled ???Modulation Of Immunostimulatory Properties Of Oligonucleotide-Based Compounds By Utilizing Modified Immunostimulatory Dinucleotides??? US 7,569,554, entitled ???Synergistic Treatment of Cancer Using Immunomers in Conjunction with Chemotherapeutic Agents??? US 7,566,702, entitled ???Immunostimulatory Oligonucleotide Multimers??? US 7,517,862, entitled ???Modulation of Immunostimulatory Properties of Oligonucleotide-based Compounds by Optimal Presentation of 5?? Ends??? US 7,498,426, entitled ???Immunostimulatory Oligonucleotide Multimers??? US 7,498,425, entitled ???Immunostimulatory Oligonucleotide Multimers??? US 7,470,674, entitled ???Immunostimulatory Properties of Oligonucleotide-based Compounds Comprising Modified Immunostimulatory Dinucleotides???

Antisense Technology

The Company??s antisense technology portfolio includes 220 patents and patent applications worldwide owned or licensed by Idera covering novel antisense compounds and methods of their use. These patents and patent applications include claims covering second-generation antisense chemistry, oral delivery of second-generation antisense compounds, and certain genes, antisense sequences, and therapeutic targets (including various TLRs and signaling molecules).

Additionally, in 2009 and early 2010, the Company was recognized three times by the Patent Board?? as one of the top 35 companies in the biotechnology field based on its technology and intellectual property advances. The Patent Board?? is an independent group that tracks and analyzes intellectual property and technology assets across 17 industries globally and publishes its results in the Wall Street Journal.

Source Idera Pharmaceuticals, Inc.